Fully automated nucleic acid testing platform combines the accuracy of molecular testing with a short turnaround time, allowing same day treatment decisions and consultations with patients. The portable m-PIMA™ Analyser brings HIV early infant diagnosis and HIV viral load testing to a wide range of decentralized settings, bypassing delays and inefficiencies associated with centralized testing.
The m-PIMA™ HIV-1/2 VL test is now commercially available and has received CE-IVD marking and WHO prequalification. This product is not available in the United States.
BENEFITS
Actionable results at the point of care, while the patient is still present
Empower decentralized decision making
Engage patients on their diagnosis and treatment
Patients lost to follow up potentially reduced
Complement central laboratory infrastructure
Manage decentralized programmes via built-in connectivity